Table 2

 Cost and health outcomes by monitoring strategy (per 100 people starting each arm), for cost effectiveness analysis, antiretroviral monitoring study, Tororo and Busia Districts, Uganda, 2003-7

Clinical/CD4/viral loadClinical/CD4Clinical
Costs ($)
Total during trial (three years)229 521194 844190 570
Laboratory monitoring CD4 and viral load*38 14251640
Antiretroviral drugs*44 40242 89746 370
Total after trial539 656431 874415 690
Total769 177626 718606 260
Health outcomes
DALYs during trial27.130.544.4
Deaths11.112.217.5
DALYs from deaths25.828.340.5
DALYs from opportunistic infections1.362.173.90
Future DALYs294.5318.6422.0
Total DALYs321.6349.1466.4

*Selected cost detail presented to show major variation across strategy.